ESC 365 - Is it safe to discontinue immunosuppression in cardiac sarcoidosis?

ESC Premium Access

Is it safe to discontinue immunosuppression in cardiac sarcoidosis?

Session: Poster session 6 - Cardiomyopathies

Topic: Myocarditis

Speaker: Doctor P. Simonen (Helsinki, FI)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Doctor Piia Simonen

Helsinki University Central Hospital, Helsinki (Finland)

0 follower

14 more presentations in this session

The electrocardiographic frontal QRS-T angle is a powerful predictor of increased mortality in patients with cardiac AL amyloidosis

Speaker: Doctor A. Turyan Medvedovsky (Jerusalem, IL)

The utility of simplified apical 4-chamber view evaluation of relative apical sparing of longitudinal strain in diagnosing AL amyloid cardiomyopathy

Speaker: Mr M. Fikrle (Jihlava, CZ)

Tafamidis and cardiovascular involvement in hereditary ATTR amyloidosis: a 10-year story

Speaker: Doctor P. Fernandes Dias M Rodrigues (Porto, PT)

Comparison of cardiopulmonary exercise test performance in infiltrative cardiomyopathy

Speaker: Ms U. Gorsi (Cincinnati, US)

The impact of inflammation on the outcome of cardiac amyloidosis

Speaker: Professor K. Klingel (Tuebingen, DE)

Access the full session

Poster session 6 - Cardiomyopathies

Speakers: Doctor P. Simonen, Doctor A. Turyan Medvedovsky, Mr M. Fikrle, Doctor P. Fernandes Dias M Rodrigues, Ms U. Gorsi...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources